The German chemical manufacturer launched Kollicoat MAE 100-55 at an industry event in Glasgow, Scotland today, describing the product as an alternative coating technology for instant and modified release medicines.
BASF stressed its product’s large particle size as its main advantage, explaining that applying it to pharmaceutical tablets generates less dust than other coating excipients.
Andres Christian Orthofer, Global communications manager, BASF Pharma Solutions told us the new excipient will be sold for a "price that we believe is competitive in the market."
He added that the product "is based on precursors that are well-established and used for other products such as Kollicoat MAE 30 DP" going on to say "It’s produced in existing facilities that are used for other enteric coating grades, by the same highly experienced personnel."
Orthofer suggested that companies the firm supplies will value the continuity.
"Our customers can expect the same supply reliability as for the remaining functional coatings from BASF Pharmaceutical Solutions."
The other main marketing pitch is that because BASF’s excipient matches has the same release profile as established pH5.5 enteric release materials, drug manufacturers could adopt it without needing to re-register their products.
This point is in keeping with comments BASF made at CPhI Worldwide last year, when it said excipient users want to be “first to be second” and are usually reluctant to be the earliest adopters of untried materials.